Delivery Order SPE2DB22D2006-SPE2DB25FW3QS
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,076.77 to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 100-62.5-25 inhalers (60-count supply). This is a firm fixed-price, competitively awarded contract with no set-aside designation, with an ultimate completion date of July 22, 2025. The award was made to AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania, the company's headquarters location, which also serves as the place of performance for...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,345.60 to AmerisourceBergen Drug Corp for the supply of Trelegy Ellipta 100-62.5-25 inhalers (60-count). This contract, awarded on August 4, 2025, with an ultimate completion date of August 5, 2025, represents a firm fixed-price delivery order with no set-aside designation. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a $12,545.94 delivery order to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 200-62.5-25 inhalers (60-count units) on July 31, 2025, with an ultimate completion date of August 1, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,554.00 to AmerisourceBergen Drug Corp for the supply of Trelegy Ellipta 100-62.5-25 inhalers (60-count units). Issued on June 9, 2025, with an ultimate completion date of June 10, 2025, this firm fixed-price delivery order was competitively awarded with no set-aside designation. The contract will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency (DLA) awarded a $18,604.96 delivery order to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 200-62.5-25 inhalers (60-count units) on September 3, 2025, with an ultimate completion date of September 4, 2025. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation. The order will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania location, where the company's corporate office is headquartered. This delivery order is...
- The Defense Logistics Agency (DLA) awarded a $22,946.07 delivery order to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 200-62.5-25, a combination inhaler medication used to treat chronic obstructive pulmonary disease. The contract was competitively awarded without set-aside provisions and carries a firm fixed price structure with an ultimate completion date of September 9, 2025. Performance will be executed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $29,315.47 delivery order to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 100-62.5-25 inhalers (60-count unit) on July 31, 2025, with an ultimate completion date of August 1, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is being fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract action under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $3,415.62 to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 100-62.5-25 inhalers (60-count units) on July 14, 2025, with completion expected by July 15, 2025. This firm fixed price delivery order represents a non-competitive award under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX), valued at $999.999 billion through December 2026. The product is being delivered to...
- The Defense Logistics Agency awarded a delivery order valued at $51,438.07 to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 200-62.5-25 inhalers (60-count supply). This firm fixed-price, non-set-aside contract was awarded on August 25, 2025, with an ultimate completion date of August 26, 2025. The order will be fulfilled from AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child award under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $19,858.14 delivery order to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 100-62.5-25 inhalers (60-count supply) under a firm fixed price contract. The award was made on September 3, 2025, with an ultimate completion date of September 4, 2025, and represents a non-competitive delivery order with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical...
- SPE2DB22D2006Indefinite Delivery Contract
- SPE2DB22D2006-SPE2DB25FW3QSDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $22,534.20 to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 100-62.5-25 inhalers (60-count supply). This firm fixed price contract, awarded on August 15, 2025, represents a competitive award with no set-aside designation and will be completed by August 18, 2025. The order will be fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major pharmaceutical distributor serving federal medical procurement needs. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.9 billion prime vendor agreement running through December 2026 that provides global pharmaceutical support for military healthcare systems. As the prime contractor on this comprehensive vehicle, AmerisourceBergen supplies an extensive portfolio of medications and medical supplies across multiple therapeutic domains to support the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. TRELEGY ELLIPTA is a combination inhaler used for chronic obstructive pulmonary disease (COPD) treatment, reflecting the company's role in delivering critical respiratory therapeutics to military personnel and beneficiaries.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $22.5k | 8/15/25 |